Clinical benefit was independent of patients’ tumor mutational burden ORLANDO, Fla. – mRNA-4157/V940, a personalized mRNA-based cancer vaccine,...
ORLANDO, Fla. – The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated...
Patients treated with the durvalumab-based regimen before and after surgery in the AEGEAN trial had a 32% reduction in...
SAN ANTONIO – Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy...
SAN ANTONIO – Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had...
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...
SAN ANTONIO – The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine...
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in...